Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-006484
Filing Date
2025-05-06
Accepted
2025-05-06 16:02:24
Documents
67
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vygr-20250331x10q.htm   iXBRL 10-Q 1368550
2 EX-10.1 vygr-20250331xex10d1.htm EX-10.1 31621
3 EX-10.2 vygr-20250331xex10d2.htm EX-10.2 21572
4 EX-31.1 vygr-20250331xex31d1.htm EX-31.1 12895
5 EX-31.2 vygr-20250331xex31d2.htm EX-31.2 13668
6 EX-32.1 vygr-20250331xex32d1.htm EX-32.1 10625
7 GRAPHIC vygr-20250331x10q006.jpg GRAPHIC 72703
  Complete submission text file 0001558370-25-006484.txt   6613185

Data Files

Seq Description Document Type Size
8 EX-101.SCH vygr-20250331.xsd EX-101.SCH 41401
9 EX-101.CAL vygr-20250331_cal.xml EX-101.CAL 54529
10 EX-101.DEF vygr-20250331_def.xml EX-101.DEF 166719
11 EX-101.LAB vygr-20250331_lab.xml EX-101.LAB 380119
12 EX-101.PRE vygr-20250331_pre.xml EX-101.PRE 279554
70 EXTRACTED XBRL INSTANCE DOCUMENT vygr-20250331x10q_htm.xml XML 1160687
Mailing Address 75 HAYDEN AVENUE LEXINGTON MA 02421
Business Address 75 HAYDEN AVENUE LEXINGTON MA 02421 857-259-5340
Voyager Therapeutics, Inc. (Filer) CIK: 0001640266 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37625 | Film No.: 25917108
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)